News and Trends 22 Jun 2022
Millions invested for progression of Lyme disease vaccine
Pfizer has agreed to invest €90.5 million ($95 million) towards a vaccination for Lyme disease. A deal has been struck with Valneva SE that will see the start of the phase 3 study of the disease’s vaccine candidate, VLA15. This is scheduled for the third quarter of this year. The investment will represent 8.1% of […]